Home›Bupropion

Bupropion

Also known as: Forfivo, Contrave, Auvelity, Wellbutrin +1 more

Route: Oral

52 interactions on record⛔ Black Box Warning

Bupropion has 52 known drug interactions based on U.S. FDA drug labeling data. 17 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Acetaminophen And Codeine Phosphate, Amantadine, Cyclobenzaprine. Patients taking Bupropion should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 52
Major: 17
Moderate: 34

Major (17)

Bupropion + Acetaminophen And Codeine Phosphate— CYP2D6 inhibitor that increases codeine plasma concentration but decreases morphine concentration, potentially causing r…
Bupropion + Amantadine— Dopaminergic drug; concomitant use with bupropion can cause CNS toxicity; use with caution.
Bupropion + Cyclobenzaprine— Postmarketing cases of serotonin syndrome reported during combined use; careful observation advised.
Bupropion + Cyclobenzaprine Hcl Er— Postmarketing cases of serotonin syndrome reported during combined use with bupropion.
Bupropion + Cyclobenzaprine Hydrochloride— Postmarketing cases of serotonin syndrome reported during combined use.
Bupropion + Deutetrabenazine— Strong CYP2D6 inhibitor that increases systemic exposure to active dihydro-metabolites of deutetrabenazine by approximat…
Bupropion + Levodopa— Dopaminergic drug; concomitant use with bupropion can cause CNS toxicity; use with caution.
Bupropion + Maois— Increased risk of hypertensive reactions when used concomitantly with bupropion.
Bupropion + Methylene Blue— Concomitant use may result in serotonin syndrome with serious CNS reactions, potentially fatal.
Bupropion + Metoclopramide— Strong CYP2D6 inhibitor that increases metoclopramide plasma concentrations and risk of extrapyramidal symptoms exacerba…
Bupropion + Metoclopramide Hydrochloride— Strong CYP2D6 inhibitor increasing metoclopramide plasma concentrations with risk of exacerbation of extrapyramidal symp…
Bupropion + Monoamine Oxidase Inhibitors (Maois)— Increased risk of hypertensive reactions when used concomitantly with bupropion.
Bupropion + Prednisone— Both agents lower seizure threshold; concurrent use requires extreme caution with low initial dosing and gradual increas…
Bupropion + Tramadol Hcl Er— CYP2D6 inhibitor that increases tramadol plasma concentration and decreases M1 concentration, resulting in increased ris…
Bupropion + Tramadol Hydrochloride— CYP2D6 inhibitor may increase tramadol plasma concentration and decrease M1 concentration, resulting in increased risk o…
Bupropion + Tramadol Hydrochloride And Acetaminophen— CYP2D6 inhibitor that increases tramadol plasma concentration and decreases M1 concentration, risking seizures, serotoni…
Bupropion + Tramadol/Apap— CYP2D6 inhibitor may increase tramadol plasma concentration and decrease M1 concentration, resulting in increased risk o…

Moderate (34)

Bupropion + Carbamazepine— CYP2B6 inducer that may decrease bupropion exposure; dose increase may be necessary but should not exceed maximum recomm…
Bupropion + Clopidogrel— CYP2B6 inhibitor that increases bupropion exposure; dosage adjustment may be necessary based on clinical response.
Bupropion + Clozapine— CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose r…
Bupropion + Desipramine— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases desipramine concentrations; consider dose reduction.
Bupropion + Efavirenz— CYP2B6 inducer that decreases bupropion exposure; dose increase may be necessary but should not exceed maximum recommend…
Bupropion + Fexinidazole— Fexinidazole induces CYP2B6, decreasing bupropion plasma concentrations and efficacy.
Bupropion + Flecainide— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases flecainide concentrations; consider dose reduction.
Bupropion + Fluoxetine— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases fluoxetine concentrations; consider dose reduction.
Bupropion + Haloperidol— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases haloperidol concentrations; consider dose reduction.
Bupropion + Imipramine— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases imipramine concentrations; consider dose reduction.
Bupropion + Ioflupane I-123— Binds to dopamine transporter with high affinity and may interfere with Ioflupane I-123 imaging results.
Bupropion + Isavuconazonium Sulfate— Concomitant administration with CRESEMBA requires caution.
Bupropion + Lemborexant— CYP2B6 substrate whose AUC is decreased by lemborexant, potentially reducing efficacy. Monitor for adequate clinical res…
Bupropion + Lopinavir— CYP2B6 inducer that decreases bupropion exposure; dose increase may be necessary but should not exceed maximum recommend…
Bupropion + Metoprolol— Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.
Bupropion + Metoprolol Tartrate— Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.
Bupropion + Metoprolol Tartrate And Hydrochlorothiazide— Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol; caution should be exercised.
Bupropion + Mifepristone— Mifepristone should be used with caution with bupropion; metabolized by CYP2B6.
Bupropion + Nortriptyline— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases nortriptyline concentrations; consider dose reduction.
Bupropion + Oliceridine— CYP2D6 inhibitor that increases oliceridine plasma concentration, resulting in increased or prolonged opioid effects. Ma…
Bupropion + Paroxetine— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases paroxetine concentrations; consider dose reduction.
Bupropion + Phenobarbital— CYP2B6 inducer that may decrease bupropion exposure; dose increase may be necessary but should not exceed maximum recomm…
Bupropion + Phenytoin— CYP2B6 inducer that may decrease bupropion exposure; dose increase may be necessary but should not exceed maximum recomm…
Bupropion + Propafenone— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases propafenone concentrations; consider dose reduction.
Bupropion + Propranolol Hydrochloride— CYP2D6 inhibitor that increases propranolol exposure. Monitor for bradycardia and hypotension.
Bupropion + Risperidone— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases risperidone concentrations; consider dose reduction.
Bupropion + Ritonavir— CYP2B6 inducer that decreases bupropion exposure; dose increase may be necessary but should not exceed maximum recommend…
Bupropion + Sertraline— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases sertraline concentrations; consider dose reduction.
Bupropion + Telotristat Ethyl— Telotristat ethyl may decrease the efficacy of bupropion by decreasing its systemic exposure. Monitor patient response a…
Bupropion + Thioridazine— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases thioridazine concentrations; consider dose reduction.
Bupropion + Ticlopidine— CYP2B6 inhibitor that increases bupropion exposure; dosage adjustment may be necessary based on clinical response.
Bupropion + Varenicline Tartrate— Varenicline did not alter bupropion pharmacokinetics, but safety of combination has not been established. Use with cauti…
Bupropion + Venlafaxine— CYP2D6 substrate; bupropion inhibits CYP2D6 and increases venlafaxine concentrations; consider dose reduction.
Bupropion + Vortioxetine— Strong CYP2D6 inhibitor increases plasma concentrations of vortioxetine. Reduce TRINTELLIX dose by half when coadministe…

Bupropion + Acetaminophen And Codeine Phosphate⚠️Major

CYP2D6 inhibitor that increases codeine plasma concentration but decreases morphine concentration, potentially causing reduced analgesic efficacy or opioid withdrawal symptoms. Discontinuation may cause increased morphine levels and potentially fatal respiratory depression.

Bupropion + Amantadine⚠️Major

Dopaminergic drug; concomitant use with bupropion can cause CNS toxicity; use with caution.

Bupropion + Cyclobenzaprine⚠️Major

Postmarketing cases of serotonin syndrome reported during combined use; careful observation advised.

Bupropion + Cyclobenzaprine Hcl Er⚠️Major

Postmarketing cases of serotonin syndrome reported during combined use with bupropion.

Bupropion + Cyclobenzaprine Hydrochloride⚠️Major

Postmarketing cases of serotonin syndrome reported during combined use.

Bupropion + Deutetrabenazine⚠️Major

Strong CYP2D6 inhibitor that increases systemic exposure to active dihydro-metabolites of deutetrabenazine by approximately 3-fold. Maximum recommended dose should not exceed 36 mg per day.

Bupropion + Levodopa⚠️Major

Dopaminergic drug; concomitant use with bupropion can cause CNS toxicity; use with caution.

Bupropion + Maois⚠️Major

Increased risk of hypertensive reactions when used concomitantly with bupropion.

Bupropion + Methylene Blue⚠️Major

Concomitant use may result in serotonin syndrome with serious CNS reactions, potentially fatal.

Bupropion + Metoclopramide⚠️Major

Strong CYP2D6 inhibitor that increases metoclopramide plasma concentrations and risk of extrapyramidal symptoms exacerbation. Dosage reduction recommended.

Bupropion + Metoclopramide Hydrochloride⚠️Major

Strong CYP2D6 inhibitor increasing metoclopramide plasma concentrations with risk of exacerbation of extrapyramidal symptoms; dosage reduction recommended.

Bupropion + Monoamine Oxidase Inhibitors (Maois)⚠️Major

Increased risk of hypertensive reactions when used concomitantly with bupropion.

Bupropion + Prednisone⚠️Major

Both agents lower seizure threshold; concurrent use requires extreme caution with low initial dosing and gradual increases.

Bupropion + Tramadol Hcl Er⚠️Major

CYP2D6 inhibitor that increases tramadol plasma concentration and decreases M1 concentration, resulting in increased risk of seizures, serotonin syndrome, and opioid withdrawal symptoms.

Bupropion + Tramadol Hydrochloride⚠️Major

CYP2D6 inhibitor may increase tramadol plasma concentration and decrease M1 concentration, resulting in increased risk of seizures, serotonin syndrome, and opioid withdrawal or toxicity.

Bupropion + Tramadol Hydrochloride And Acetaminophen⚠️Major

CYP2D6 inhibitor that increases tramadol plasma concentration and decreases M1 concentration, risking seizures, serotonin syndrome, opioid withdrawal, and respiratory depression.

Bupropion + Tramadol/Apap⚠️Major

CYP2D6 inhibitor may increase tramadol plasma concentration and decrease M1 concentration, resulting in increased risk of seizures, serotonin syndrome, and opioid withdrawal or toxicity.

Bupropion + Carbamazepine🟡Moderate

CYP2B6 inducer that may decrease bupropion exposure; dose increase may be necessary but should not exceed maximum recommended dose.

Bupropion + Clopidogrel🟡Moderate

CYP2B6 inhibitor that increases bupropion exposure; dosage adjustment may be necessary based on clinical response.

Bupropion + Clozapine🟡Moderate

CYP2D6 or CYP3A4 inhibitor that can increase clozapine levels and lead to adverse reactions. Close monitoring and dose reduction may be necessary.

Bupropion + Desipramine🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases desipramine concentrations; consider dose reduction.

Bupropion + Efavirenz🟡Moderate

CYP2B6 inducer that decreases bupropion exposure; dose increase may be necessary but should not exceed maximum recommended dose.

Bupropion + Fexinidazole🟡Moderate

Fexinidazole induces CYP2B6, decreasing bupropion plasma concentrations and efficacy.

Bupropion + Flecainide🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases flecainide concentrations; consider dose reduction.

Bupropion + Fluoxetine🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases fluoxetine concentrations; consider dose reduction.

Bupropion + Haloperidol🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases haloperidol concentrations; consider dose reduction.

Bupropion + Imipramine🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases imipramine concentrations; consider dose reduction.

Bupropion + Ioflupane I-123🟡Moderate

Binds to dopamine transporter with high affinity and may interfere with Ioflupane I-123 imaging results.

Bupropion + Isavuconazonium Sulfate🟡Moderate

Concomitant administration with CRESEMBA requires caution.

Bupropion + Lemborexant🟡Moderate

CYP2B6 substrate whose AUC is decreased by lemborexant, potentially reducing efficacy. Monitor for adequate clinical response and consider dose increase if needed.

Bupropion + Lopinavir🟡Moderate

CYP2B6 inducer that decreases bupropion exposure; dose increase may be necessary but should not exceed maximum recommended dose.

Bupropion + Metoprolol🟡Moderate

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.

Bupropion + Metoprolol Tartrate🟡Moderate

Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.

Bupropion + Metoprolol Tartrate And Hydrochlorothiazide🟡Moderate

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol; caution should be exercised.

Bupropion + Mifepristone🟡Moderate

Mifepristone should be used with caution with bupropion; metabolized by CYP2B6.

Bupropion + Nortriptyline🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases nortriptyline concentrations; consider dose reduction.

Bupropion + Oliceridine🟡Moderate

CYP2D6 inhibitor that increases oliceridine plasma concentration, resulting in increased or prolonged opioid effects. May require less frequent dosing and close monitoring for respiratory depression.

Bupropion + Paroxetine🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases paroxetine concentrations; consider dose reduction.

Bupropion + Phenobarbital🟡Moderate

CYP2B6 inducer that may decrease bupropion exposure; dose increase may be necessary but should not exceed maximum recommended dose.

Bupropion + Phenytoin🟡Moderate

CYP2B6 inducer that may decrease bupropion exposure; dose increase may be necessary but should not exceed maximum recommended dose.

Bupropion + Propafenone🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases propafenone concentrations; consider dose reduction.

Bupropion + Propranolol Hydrochloride🟡Moderate

CYP2D6 inhibitor that increases propranolol exposure. Monitor for bradycardia and hypotension.

Bupropion + Risperidone🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases risperidone concentrations; consider dose reduction.

Bupropion + Ritonavir🟡Moderate

CYP2B6 inducer that decreases bupropion exposure; dose increase may be necessary but should not exceed maximum recommended dose.

Bupropion + Sertraline🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases sertraline concentrations; consider dose reduction.

Bupropion + Telotristat Ethyl🟡Moderate

Telotristat ethyl may decrease the efficacy of bupropion by decreasing its systemic exposure. Monitor patient response and consider increasing bupropion dosage if necessary.

Bupropion + Thioridazine🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases thioridazine concentrations; consider dose reduction.

Bupropion + Ticlopidine🟡Moderate

CYP2B6 inhibitor that increases bupropion exposure; dosage adjustment may be necessary based on clinical response.

Bupropion + Varenicline Tartrate🟡Moderate

Varenicline did not alter bupropion pharmacokinetics, but safety of combination has not been established. Use with caution.

Bupropion + Venlafaxine🟡Moderate

CYP2D6 substrate; bupropion inhibits CYP2D6 and increases venlafaxine concentrations; consider dose reduction.

Bupropion + Vortioxetine🟡Moderate

Strong CYP2D6 inhibitor increases plasma concentrations of vortioxetine. Reduce TRINTELLIX dose by half when coadministered.

Bupropion + Vareniclineℹ️Unknown

Varenicline did not alter bupropion steady-state pharmacokinetics, but safety of combination has not been established.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.